Navigation Links
Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
Date:2/21/2008

NEW YORK, Feb. 21 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) will hold a conference call on Monday, February 25, 2008 at 8:30 a.m. EST to discuss the fourth quarter and year-end 2007 financial results and business outlook for 2008. Michael S. Weiss, Chairman and Chief Executive Officer of the Company, will host the call. Keryx will announce its financial results for this period in a press release to be issued prior to the call.

In order to participate in the conference call, please call 1-877-874-1565 (U.S.), 1-719-325-4750 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at http://www.keryx.com, for a period of 15 days after the call.

The press release announcing our financial results for this period will be posted on the Company's website, http://www.keryx.com, prior to the call.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals, Inc. is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx's lead compound under development is Sulonex(TM) (sulodexide) oral gelcaps, previously referred to as KRX-101, a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life-threatening kidney disease caused by diabetes. Sulonex is in a pivotal Phase 3 and Phase 4 clinical program under a Special Protocol Assessment with the Food & Drug Administration. Additionally, Keryx is developing Zerenex(TM), an oral, iron- based compound that has the capacity to bind phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated serum phosphorous levels) in patients with end- stage renal disease. Keryx is also developing clinical-stage oncology compounds, including KRX-0401 (perifosine), a novel, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. Keryx also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.

CONTACT: Lauren Fischer, Director - Investor Relations of Keryx Biopharmaceuticals, Inc., +1-212-531-5965, lfischer@keryx.com


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
2. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
3. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
4. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
7. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
8. Keryx Biopharmaceuticals Announces Additions to Management Team
9. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
10. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
11. Avicena Group to Present at Noble Financial Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2020)... ... , ... In a free session on Tuesday, March 10, 2020 ... Dilworth, BS, MS, Vice President Rare, Orphan and Pediatric Diseases, and Rachael Young, Associate ... support patients, sites and sponsors. , When planning a rare disease clinical trial, drug ...
(Date:2/19/2020)... Conn. (PRWEB) , ... February 18, 2020 , ... ... develops tools for characterizing microbiome populations down to the strain level, recently unveiled ... easy-to-use kit designed for efficient and unbiased isolation of high molecular weight (HMW) ...
(Date:2/11/2020)... ... February 11, 2020 , ... ... services in North America, today announced that the City of Fort Worth has ... biosolids management needs. Commencing in April of 2020, Synagro will assume operation of ...
(Date:2/3/2020)... Hungary and CAMBRIDGE, Mass. (PRWEB) , ... February ... ... in Budapest with US offices in Cambridge, MA, announce that OmniType, the 11-locus, ... Program (EAP) from today. OmniType is a best-in-class product featuring locus-multiplexing and short ...
Breaking Biology Technology:
(Date:3/27/2020)... ... 2020 , ... ixlayer, an industry leader in technology solutions ... launch and scale COVID-19 clinical testing. The ixlayer platform, already encompassing the security ... COVID-19 specific content and user flows, allowing physicians/health systems, organizations, and university groups ...
(Date:3/20/2020)... (PRWEB) , ... March 20, 2020 , ... ... development of human embryonic stem cell (ESC) derived mesenchymal stem cells (hES-MSC), through ... for the treatment of neurological, autoimmune, and rare orphan diseases, today announced that ...
(Date:3/19/2020)... ... March 19, 2020 , ... The former Jason "Furious" Styles of ... the informational show "In Depth". The TV program highlights a large variety of subjects ... on a new episode with a dive into the world of applied academics. The ...
Breaking Biology News(10 mins):